Bill Texts: NJ A3793 | 2016-2017 | Regular Session

Bill Title: Clarifies that product approval from U.S. Food and Drug Administration is not required for drug manufacturer to file registration statement, and specifies timeframe by which DOH must review registration statements.

Sponsorship: Slight Partisan Bill (Democrat 6-2)

Status: (Introduced - Dead) 2016-10-20 - Substituted by S2024 [A3793 Detail]

Bill Drafts

RevisionDateFormatSourceView
Introduced2016-05-23HTML/TextLinkView

Amendments

AmendmentDateDispositionFormatSourceView
No bill amendments currently on file for New Jersey A3793

Supplemental Documents

TitleDescriptionDateFormatSourceView
No supplemental documents for New Jersey A3793 currently on file.

feedback